AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows:

1-47. Canceled.

48. (Currently Amended) A method for eliciting in a host an antibody that specifically binds to a second inner core of lipopolysaccharide of ~~recognizes~~ *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12, comprising administering to said host an immunogenic composition, said immunogenic composition comprising [[an]] a first inner core of a *Neisseria* lipopolysaccharide (LPS) and is substantially free from outer core lipopolysaccharide, wherein a phosphoethanolamine moiety is linked to position 3 of a HepII moiety of said first inner core ~~of said *Neisseria* LPS~~, wherein said antibody ~~binds to [[an]] a inner core LPS of *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12; and~~ is capable of conferring passive protection against a galE mutant of an L3 immunotype *Neisseria meningitidis* strain.

49. (Cancelled)

50-54. (Cancelled)

55. (Currently Amended) A method of immunizing a host against *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12, comprising administering to said host an immunogenic composition, said immunogenic composition comprising [[an]] a first inner core of a *Neisseria* lipopolysaccharide (LPS) and is substantially free from outer core lipopolysaccharide, wherein a phosphoethanolamine moiety is linked to position 3 of a HepII moiety of said

first inner core ~~of said *Neisseria* LPS~~, whereby an antibody is elicited that binds to [[an]] a second inner core LPS of *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12; and is capable of conferring passive protection against a galE mutant of an L3 immunotype *Neisseria meningitidis* strain.

56. (Cancelled)

57-61. (Canceled)

62. (Currently Amended) The method of claim 48, wherein said second inner core ~~LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12~~ is accessible to said antibody in a presence of an outer core LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12.

63. (Currently Amended) The method of claim 48, wherein said second inner core ~~LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12~~ is accessible to said antibody in a presence of a bacterial capsule of a *Neisseria meningitidis* strain.

64. (Currently Amended) The method of claim 48, wherein ~~said immunogenic composition comprises~~ said first inner core ~~of a *Neisseria* LPS~~ is conjugated to a protein or peptide.

65. (Currently Amended) The method of claim 48, wherein said first inner core ~~of a *Neisseria* LPS~~ is an inner core of a *Neisseria meningitidis* LPS.

66. (Currently Amended) The method of claim 55, wherein said second inner core ~~LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12~~ is accessible to said antibody in a presence of an outer core LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12.

67. (Currently Amended) The method of claim 55, wherein said second inner core ~~LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12~~ is accessible to said antibody in a presence of a bacterial capsule of a *Neisseria meningitidis* strain.

68. (Currently Amended) The method of claim 55, wherein said ~~immunogenic composition comprises said~~ first inner core ~~of a *Neisseria* LPS~~ is conjugated to a protein or peptide.

69. (Currently Amended) The method of claim 55, wherein said first inner core ~~of a *Neisseria* LPS~~ is an inner core of a *Neisseria meningitidis* LPS.

70. (Currently Amended) A method for eliciting in a host an antibody that recognizes a majority of naturally occurring strains of *Neisseria meningitidis*, comprising administering to said host an immunogenic composition, said immunogenic composition comprising [[an]] a first inner core of a *Neisseria* lipopolysaccharide (LPS) and is substantially free from outer core lipopolysaccharide, wherein a phosphoethanolamine moiety is linked to position 3 of a HepII moiety of said first inner core ~~of said *Neisseria* LPS~~, wherein said antibody binds to [[an]] a second inner core LPS of a majority of naturally occurring strains of *Neisseria*

meningitidis; and is capable of conferring passive protection against a galE mutant of an L3 immunotype *Neisseria meningitidis* strain.

71. (Cancelled)

72. (Currently Amended) The method of claim 70, wherein said second inner core ~~LPS of said majority of naturally occurring strains of *Neisseria meningitidis*~~ is accessible to said antibody in a presence of an outer core LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12.

73. (Currently Amended) The method of claim 70, wherein said second inner core ~~LPS of said majority of naturally occurring strains of *Neisseria meningitidis*~~ is accessible to said antibody in a presence of a bacterial capsule of a *Neisseria meningitidis* strain.

74. (Currently Amended) The method of claim 70, wherein ~~said immunogenic composition comprises~~ said first inner core ~~of a *Neisseria* LPS~~ is conjugated to a protein or peptide.

75. (Currently Amended) The method of claim 70, wherein said first inner core of a *Neisseria* LPS is an inner core of a *Neisseria meningitidis* LPS.

76. (Currently Amended) A method of immunizing a host against a majority of naturally occurring strains of *Neisseria meningitidis*, comprising administering to said host an immunogenic composition, said immunogenic composition comprising [[an]] a first inner core of a *Neisseria* lipopolysaccharide (LPS) and is substantially free from outer core lipopolysaccharide, wherein a

phosphocthanolaminc moiety is linked to position 3 of a HepII moiety of said first inner core of said *Neisseria* LPS, whereby an antibody is elicited that binds to [[an]] a second inner core LPS of a majority of naturally occurring strains of *Neisseria meningitidis*; and is capable of conferring passive protection against a galE mutant of an L3 immunotype *Neisseria meningitidis* strain.

77. (Cancelled)

78. (Currently Amended) The method of claim 76, wherein said second inner core ~~LPS of said majority of naturally occurring strains of *Neisseria meningitidis*~~ is accessible to said antibody in a presence of an outer core LPS of said *Neisseria meningitidis* immunotypes L1, L3, L7, L8, L9, L10, L11, and L12.

79. (Currently Amended) The method of claim 76, wherein said second inner core ~~LPS of said majority of naturally occurring strains of *Neisseria meningitidis*~~ is accessible to said antibody in a presence of a bacterial capsule of a *Neisseria meningitidis* strain.

80. (Currently Amended) The method of claim 76, wherein said ~~immunogenic composition comprises said~~ first inner core ~~of a *Neisseria* LPS~~ is conjugated to a protein or peptide.

81. (Currently Amended) The method of claim 76, wherein said first inner core of a *Neisseria* LPS is an inner core of a *Neisseria meningitidis* LPS.